KRYS vs. BCRX, INBX, NK, TSHA, ITOS, NBIX, TECH, QGEN, RGEN, and PCVX
Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include BioCryst Pharmaceuticals (BCRX), Inhibrx (INBX), NantKwest (NK), Taysha Gene Therapies (TSHA), iTeos Therapeutics (ITOS), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), and Vaxcyte (PCVX). These companies are all part of the "medical" sector.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
Krystal Biotech has a net margin of 0.00% compared to Krystal Biotech's net margin of -58.69%. Krystal Biotech's return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.
85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
BioCryst Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 121.87%. Krystal Biotech has a consensus price target of $177.63, suggesting a potential upside of 8.03%. Given Krystal Biotech's higher possible upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Krystal Biotech.
BioCryst Pharmaceuticals received 199 more outperform votes than Krystal Biotech when rated by MarketBeat users. However, 66.83% of users gave Krystal Biotech an outperform vote while only 66.43% of users gave BioCryst Pharmaceuticals an outperform vote.
Krystal Biotech has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 3 mentions for Krystal Biotech. BioCryst Pharmaceuticals' average media sentiment score of 1.18 beat Krystal Biotech's score of 1.00 indicating that Krystal Biotech is being referred to more favorably in the news media.
BioCryst Pharmaceuticals has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.
Summary
Krystal Biotech beats BioCryst Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Krystal Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Krystal Biotech Competitors List
Related Companies and Tools
